Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson’s role will be pivotal in ensuring the medical, …
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is gearing up to showcase critical research at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled from October 29 to …
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced a successful outcome from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA has given …
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their …
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that its Founder, President, and CEO, Maria L. Maccecchini, Ph.D., will be actively participating in the H.C. Wainwright 26th Annual Global …
Annovis Bio’s CEO to Present at H.C. Wainwright Global Investment Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced its financial results for the second quarter ending June 30, 2024, along with significant business updates. The company highlighted positive …
Annovis Bio Reports Q2 2024 Financial Results and Business Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made a significant leap in the field of neurodegenerative disease treatment with the issuance of a U.S. patent for its lead …
Annovis Bio Secures Patent for Landmark TBI Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More